Open an account

Immuron

IMRN · ASX

$0.9535+$0.0042 (+0.44%)TodayMarket closed ·
Prev close $0.9493

About IMRN

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), and IMM-529.

Employees
7
Headquarters
Melbourne, Victoria
Listed
Apr 30, 1999
Sector
Health Care
Industry
Biotechnology
Website
immuron.com.au

IMRN key statistics

Market cap
12.91M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
52.02K
Volume
7.57K
Open price
$0.942
High today
$0.986
Low today
$0.932
52 Week high
$2.25
52 Week low
$0.6765

Immuron (IMRN) at a glance

As of Oct 23, 2026, Immuron (IMRN) shares are priced at $0.9535, giving the company a market cap of 12.91M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.932 and $0.986. The current price is 2.3% above the day's low and 3.3% below its high.

Volume so far is 7.57K shares, below the average of 52.02K shares a day.

Over the past year Immuron has ranged from $0.6765 to $2.25, and now sits 18% of the way up that range.

IMRN news

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Avi Kapoor

    Gold Falls Over 1%; American Outdoor Brands Shares Jump After Q1 Results

  • Avi Kapoor

    Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August

  • Henry Khederian

    Immuron Stock Surges Friday: What's Driving the Action?

  • Market-Moving News for September 4th

  • Press releaseGlobe Newswire

    Immuron New U.S. Department of Defense Award & Clinical Trial Update

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.